Semaglutide vs Tirzepatide
The two most effective approved weight loss medications compared—semaglutide (GLP-1 agonist) vs tirzepatide (dual GLP-1/GIP agonist).
Last updated: 2026-02-04
Semaglutide and tirzepatide represent the two most effective approved pharmaceutical treatments for obesity and type 2 diabetes. While semaglutide revolutionised the field as a highly effective GLP-1 receptor agonist, tirzepatide raised the bar further with its dual GLP-1/GIP mechanism.
This comparison examines the key differences between these medications to help healthcare providers and patients make informed treatment decisions.
**Important Note:** Both are prescription-only medications requiring medical supervision. This is educational information, not a recommendation for one over the other.
Quick Comparison Table
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Weight Loss (Trials) | ~15-17% body weight | ~20-22% body weight |
| HbA1c Reduction | 1.5-2.0% | 2.0-2.5% |
| Dosing | Once weekly | Once weekly |
| Max Dose | 2.4mg (Wegovy) | 15mg (Zepbound) |
| CV Outcomes Data | Yes (SUSTAIN-6, SELECT) | Trials ongoing |
| FDA Approval | 2017 (diabetes), 2021 (obesity) | 2022 (diabetes), 2023 (obesity) |
| Oral Option | Yes (Rybelsus) | In development |
| Manufacturer | Novo Nordisk | Eli Lilly |
| UK Availability | Available (supply constraints) | Available (newer) |
Single vs Dual Receptor Agonism
Semaglutide
Semaglutide: GLP-1 Receptor Agonist
Semaglutide activates only the GLP-1 receptor, producing: - Glucose-dependent insulin secretion - Glucagon suppression - Delayed gastric emptying - Central appetite suppression
This single-receptor approach has proven highly effective, with semaglutide becoming the most-prescribed medication in its class.
Tirzepatide
Tirzepatide: Dual GLP-1/GIP Agonist
Tirzepatide activates both GLP-1 and GIP receptors, producing: - All the effects of GLP-1 activation - Additional GIP-mediated insulin secretion - Enhanced central appetite effects - Possible direct adipose tissue effects
The dual mechanism appears to produce synergistic effects, explaining the superior efficacy seen in trials.
Clinical Trial Evidence
Semaglutide Clinical Studies
Design: Meta-analysis
Participants: 2,258 participants
Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.
View study — PubMed 39719170Design: Meta-analysis
Participants: 2,372 participants
In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.
View study — PubMed 40186344Design: Meta-analysis
Participants: 246 participants
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss.
View study — PubMed 38286487Design: Meta-analysis
Participants: 28 participants
Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.
View study — PubMed 38613667Tirzepatide Clinical Studies
Design: Meta-analysis
Participants: 2,258 participants
Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.
View study — PubMed 39719170Design: Meta-analysis
Participants: 2,372 participants
In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.
View study — PubMed 40186344Design: Meta-analysis
Participants: 60,307 participants
Y. was engaged in advisory boards and lectures with Novo Nordisk, Eli Lilly, Rhythm and Regeneron.
View study — PubMed 41039116Design: Meta-analysis
Participants: 246 participants
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss.
View study — PubMed 38286487Benefits Comparison
Semaglutide Unique Benefits
- Longer track record and more real-world experience
- Extensive cardiovascular outcomes data (SELECT, SUSTAIN-6)
- Oral formulation available (Rybelsus)
- Well-characterised side effect profile
- More widely available currently
Shared Benefits
- Highly effective for weight loss and diabetes
- Once-weekly dosing
- Improvements in blood pressure and lipids
- Reduced cardiovascular risk (proven for semaglutide; expected for tirzepatide)
Tirzepatide Unique Benefits
- Greater weight loss in head-to-head trials
- Superior glucose control
- Potentially better tolerability (some data suggests less nausea)
- Greater liver fat reduction
- Higher rates of diabetes remission
Research & Evidence
Semaglutide Research
STEP trials demonstrated 15-17% weight loss. SUSTAIN-6 and SELECT trials showed cardiovascular risk reduction. Extensive post-marketing data available.
Tirzepatide Research
SURMOUNT trials showed 20-22% weight loss. SURPASS-2 showed superiority over semaglutide 1mg. Cardiovascular outcomes trials ongoing.
Head-to-Head Analysis
SURPASS-2 compared tirzepatide to semaglutide 1mg (not the 2.4mg obesity dose). Tirzepatide showed greater weight loss (12.4kg vs 6.2kg) and HbA1c reduction. A direct comparison at maximum doses has not been conducted.
Protocol Comparison
Semaglutide Protocol
Gradual escalation from 0.25mg to 2.4mg over 16-20 weeks. Take on same day each week.
Tirzepatide Protocol
Gradual escalation from 2.5mg to 15mg over 20+ weeks. Take on same day each week.
Combined Use
These medications should NOT be combined. They have overlapping mechanisms and combination would increase adverse effects without clear additional benefit.
Safety Profiles
Semaglutide Safety
Common: GI effects (nausea, vomiting, diarrhoea). Rare: pancreatitis, gallbladder disease. Contraindicated in MTC/MEN2 history.
Tirzepatide Safety
Similar GI profile to semaglutide; some data suggests slightly better tolerability. Hair loss reported in weight loss trials. Same class warnings apply.
The Verdict: When to Choose Which?
Choose Semaglutide When:
- Cardiovascular risk reduction is priority (proven outcomes data)
- Oral administration preferred (Rybelsus available)
- Longer safety track record important
- Cost or insurance coverage favours semaglutide
Choose Tirzepatide When:
- Maximum weight loss is the primary goal
- Superior glucose control needed
- Significant liver fat/NAFLD present
- Previous inadequate response to GLP-1 agonist
Consider Combining When:
- NOT recommended—overlapping mechanisms, increased risk without benefit
Frequently Asked Questions
Conclusion
Both semaglutide and tirzepatide are highly effective treatments for obesity and diabetes. Tirzepatide shows greater efficacy in trials, while semaglutide has more cardiovascular outcomes data and a longer track record. The choice between them should be individualised based on patient factors, goals, and medical guidance.
*Always consult accredited suppliers and qualified healthcare professionals in your jurisdiction.*
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Semaglutide nor Tirzepatide is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.